Madrigal Pharmaceuticals (MDGL) Debt Ratio (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has reported Debt Ratio for 12 consecutive years, with 0.27 the latest figure, recorded in Q2 2026.

• In Q2 2026, Debt Ratio rose 134.86% year-over-year to 0.27; the TTM figure through Jun 2026 stood at 0.27 (up 134.86% YoY), while the FY2025 annual figure was 0.27, up 139.21% from the prior year.
• Debt Ratio retreated to 0.27 in Q2 2026 per MDGL's latest filing, from 0.28 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.63 in Q3 2023 and bottomed at 0.11 in Q2 2024.
• Historically, Debt Ratio has averaged 0.25 across 5 years, with a median of 0.25 in 2025.
• Annual changes were most pronounced in 2024 — Debt Ratio slumped 82.56% — and 2025, when it soared 139.21%.
• Madrigal Pharmaceuticals' Debt Ratio stood at 0.14 in 2022, then surged by 32.62% to 0.18 in 2023, then slumped by 37.43% to 0.11 in 2024, then soared by 139.21% to 0.27 in 2025, then climbed by 1.47% to 0.27 in 2026.
• Business Quant data shows MDGL's Debt Ratio at 0.27 in Q2 2026, 0.28 in Q1 2026, and 0.27 in Q4 2025.